ArticleNanoscale research letters2018
Antibacterial Activity of In Situ Prepared Chitosan/Silver Nanoparticles Solution Against Methicillin-Resistant Strains of Staphylococcus aureus.
Article in Nanoscale research letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Preparation and Physicochemical Characterization of Chitosan-Coated Iron Oxide Nanoparticles Conjugated with Oxacillin: Antimicrobial, Antibiofilm, and Biocompatibility Activities against MRSA Staphylococcus aureus.Applied biochemistry and biotechnology · 2026Article
- Metallic nanoparticles in the treatment of staphylococcus infections: a scoping review.BMC pharmacology & toxicology · 2025Article
- Synthesis of silver nanoparticles reduced by Bingöl propolis and evaluation of antioxidant, anticancer and cytotoxic activities in PC-3 cells.Molecular biology reports · 2025Article
- A Comprehensive Review of Nanomaterials as Potential Weapons against Multidrug-resistantPharmaceutical nanotechnology · 2025Review
- Nanosystems for the Encapsulation of Natural Products: The Case of Chitosan Biopolymer as a Matrix.Pharmaceutics · 2020Review
- WONanoscale research letters · 2019Article
- UV cross-linked polyvinylpyrrolidone electrospun fibres as antibacterial surfaces.Science and technology of advanced materials · 2019Article
- Augmented antibacterial activity of ampicillin with silver nanoparticles against methicillin-resistant Staphylococcus aureus (MRSA).The Journal of antibiotics · 2019Article
- Applications of Noble Metal-Based Nanoparticles in Medicine.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvestigation of new effective drugs against the methicillin-resistant strains of Staphylococcus aureus (MRSA) is an urgent issue of modern medicine. Antiseptics as an alternative of antibiotics are strong, sustained, and active preparations against resistant strains and do not violate microbiocenosis. MATERIALS AND
methodsThe activity of in situ prepared chitosan-Ag nanoparticles (Ag NPs) solution with different component ratio was tested against MRSA isolated from patients. Ag NPs were synthesized via chemical reduction method using green chemistry approach. In order to improve antimicrobial activity and dispersibility of Ag NPs, surface modification of Ag NPs by cetrimonium bromide (CTAB) was performed. Ag NPs and chitosan-Ag NPs solution were characterized using X-ray diffraction, transmission electron microscopy, infrared spectroscopy, and spectrophotometric measurements. RESULTS AND
conclusionsThe results of XRD, FTIR, UV-Vis, and TEM measurements confirmed the chemical composition of chitosan and Ag NPs and their high purity. Chitosan-AgNPs solutions have shown their superior antimicrobial efficacy compared to its pure forms. At the same time, in situ preparation of chitosan-Ag NPs solution (chitosan powder 6.0 μg/ml, Ag/CTAB NPs) was not possible due to the precipitation of the components. This result is very promising and may be considered as an effective solution in fighting against drug-resistant bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.